Vectura and Unilever Ventures announce the spin out of specialty pharmaceutical company Pharmakodex
PharmaKodex is developing a pipeline of improved medicinal products, focusing on re-purposing existing drugs for new indications or combinations, or to provide an improved route of administration. The PharmaKodex development pipeline currently comprises 7 prescription products and 6 OTC products.
PharmaKodex has initiated operations with a strong management team. Chief Executive Officer, Mr Rod Richards, held senior management roles in business and commercial development at Glaxo and SmithKline Beecham, and most recently was CEO at Microscience PLC where he led the business from start up to a successful trade sale in 2005. Prof. John Staniforth, currently Chief Scientific Officer at Vectura, will move to PharmaKodex whilst maintaining a scientific advisory role at Vectura.
Vectura and Unilever Ventures will each retain a significant shareholding in PharmaKodex. Further equity financing will come from specialist venture capital investors.
Most read news
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.